Biodexa Pharmaceuticals Plc
BDRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BDRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BDRX
Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company focused on developing product candidates for diseases with unmet medical needs, currently without approved products or recurring revenues and facing significant financial uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company focused on developing product candidates for diseases with unmet medical needs, currently without approved products or recurring revenues and facing significant financial uncertainty.
- Biodexa has incurred significant losses since inception, with a net loss of £6.25 million for the year ended December 31, 2025, and an accumulated deficit of £155.67 million [sec · filed 2026-03-27].
- As of December 31, 2025, the company reported cash & equivalents of $8.5M, shareholders' equity of $3.2M, and total debt of $0.6M [sec].
- The company has no sources of recurring revenue and its product candidates are in clinical or preclinical development phases, with no assurance of regulatory approval or commercialization [sec · filed 2026-03-27].
- Biodexa's ability to continue as a going concern is uncertain, as it requires additional financing in the short term to fund operations and development activities [sec · filed 2026-03-27].
- The company faces risks of clinical trial delays, regulatory hurdles, and dependence on finding licensing partners to advance its product candidates [sec · filed 2026-03-27].
What works
- The company is actively developing product candidates targeting areas with unmet medical needs, which could address significant market opportunities if approved [sec · filed 2026-03-27].
- Biodexa has a pipeline of candidates in clinical or preclinical stages, indicating ongoing R&D efforts despite financial constraints [sec · filed 2026-03-27].
What to weigh
- Biodexa has no approved products, no recurring revenue, and an accumulated deficit of £155.67 million as of December 31, 2025, reflecting a history of losses [sec · filed 2026-03-27].
- The company requires additional financing in the short term, and there is substantial doubt about its ability to continue as a going concern [sec · filed 2026-03-27].
- Clinical trial delays, regulatory approval uncertainties, and dependence on licensing partners pose significant risks to the company's development timeline and financial stability [sec · filed 2026-03-27].
- Even if product candidates are approved, revenue generation is uncertain and depends on successful commercialization and market acceptance [sec · filed 2026-03-27].
From the filings
Quoted directly from source documents.
The company has incurred significant losses and has an accumulated deficit.
“For the year ended December 31, 2025, we had an accumulated deficit of £155.67 million.”
SEC filings · March 27, 2026
There is substantial doubt about the company's ability to continue as a going concern.
“Our requirement for additional financing in the short-term represents a material uncertainty that raises substantial doubt about our ability to continue as a going concern.”
SEC filings · March 27, 2026
The company has no approved products and is in early-stage development.
“Our operations are in early-stage development with no sources of recurring revenue and there is no assuranc”
SEC filings · March 27, 2026
Clinical trial delays could harm the company's business.
“delays in the completion of, or termination of, any ongoing or future clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed”
SEC filings · March 27, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Requires additional financing in the short term; substantial doubt about ability to continue as a going concern [sec · filed 2026-03-27].
- No approved products or revenue — No sources of recurring revenue; all candidates are in clinical/preclinical stages with no assurance of approval [sec · filed 2026-03-27].
- Clinical and regulatory delays — Clinical trials may be delayed or terminated; regulatory approval processes are lengthy and uncertain [sec · filed 2026-03-27].
- Dependence on licensing partners — Success depends on finding licensing partners; no guarantee of establishing agreements on commercially reasonable terms [sec · filed 2026-03-27].
What to watch
- Ability to secure additional financing to fund operations and development, as the company has a going concern uncertainty [sec · filed 2026-03-27].
- Progress and results of ongoing or planned clinical trials for product candidates, which are critical for regulatory advancement [sec · filed 2026-03-27].
- Any announcements regarding licensing or partnership agreements, which are essential for commercialization and revenue generation [sec · filed 2026-03-27].
- Regulatory milestones, such as submissions or feedback from the FDA, EMA, or MHRA, which will determine the path to approval [sec · filed 2026-03-27].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Biodexa Pharmaceuticals Plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Biodexa Pharmaceuticals Plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
5.2 months
D/E 0.59
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of Apr 28, 2026- % of float
- 6.3%
- Days to cover
- 0.0
- Shares short
- 40,924
- Daily short volume (Jul 15, 2026)
- 53.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BDRX short interestFrequently asked questions
What is the AI investment thesis for Biodexa Pharmaceuticals Plc?
Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company focused on developing product candidates for diseases with unmet medical needs, currently without approved products or recurring revenues and facing significant financial uncertainty.
Who is the CEO of Biodexa Pharmaceuticals Plc?
Mr. Stephen Anthony Stamp is the chief executive officer of Biodexa Pharmaceuticals Plc (BDRX).
Where is Biodexa Pharmaceuticals Plc headquartered?
Biodexa Pharmaceuticals Plc (BDRX) is headquartered in Cardiff, United Kingdom.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.